Key facts
- This page summarizes Daniel Patrick O'Day's Form 4 filing for GILEAD SCIENCES, INC. (GILD).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Jun 2022, 19:59.
Daniel Patrick O'Day - 10 Jun 2022 Form 4 Insider Report for GILEAD SCIENCES, INC. (GILD)
- Reporting relationship
- Chairman & CEO, Director
- Issuer ticker
- GILD
- Reported as of
- 10 Jun 2022
- Net transaction value
- -$93,479
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2022, 19:59:10 UTC
- Prior SEC filing
- 14 Mar 2022
- Next SEC filing
- 12 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Edward S. Son by Power of Attorney for Daniel P. O'Day
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Daniel Patrick O'Day filed Form 4 for GILEAD SCIENCES, INC. (GILD) on 13 Jun 2022.
Change
- Previous filing in this sequence was filed on 14 Mar 2022.
- Current net transaction value: -$93,479.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
GILD
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +3,300
- Change %
- +1.3%
- Price
- Shares after
- 252,644
- Date
- 10 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
GILD
transaction
Common Stock
Tax liability
- Transaction value
- $93,479
- Shares
- -1,539
- Change %
- -0.61%
- Price
- $60.74
- Shares after
- 251,105
- Date
- 10 Jun 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
GILD
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- Shares
- -3,300
- Change %
- -2.4%
- Price
- Shares after
- 134,014
- Date
- 10 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,300
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
Footnote F2
The restricted stock units have a four-year vesting schedule. 25% vest on the first anniversary of the date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested.